{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:54:57Z","timestamp":1675349697764},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0067734","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T21:10:07Z","timestamp":1373404207000},"page":"e67734","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil"],"prefix":"10.1371","volume":"8","author":[{"given":"Halime Silva","family":"Barcaui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerson Carreiro","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Beatriz","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"Brand\u00e3o-Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcia Maria","family":"Amendola Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Feij\u00f3","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"ref1","first-page":"831","article-title":"Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin infec Dis","volume":"34(6)","author":"KE Sherman","year":"2010"},{"key":"ref2","first-page":"1","article-title":"Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur. J. Epidemiology","volume":"15","author":"V Soriano","year":"1999"},{"key":"ref3","first-page":"562","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis","volume":"33","author":"CS Graham","year":"2001"},{"key":"ref4","first-page":"466","article-title":"Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr","volume":"26","author":"ES Daar","year":"2001"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/319273","article-title":"Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis c virus infection","volume":"Dis","author":"MV Ragni","year":"2001","journal-title":"J Infect"},{"key":"ref6","first-page":"1","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol","volume":"26","author":"B Soto","year":"1997"},{"key":"ref7","first-page":"492","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis","volume":"32","author":"I Bica","year":"2001"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1086\/321819","article-title":"Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection","volume":"Dis","author":"HK Monga","year":"2001","journal-title":"Clin Infect"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study","volume":"166","author":"R Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref10","first-page":"438","article-title":"Peginterferon-alfa-2a+ribavirin vs interferon-alfa-2a+ribavirin in the treatment of HCV in HIV\/HCV co-infection. N Engl J Med","volume":"351","author":"FJ Torriani","year":"2004"},{"key":"ref11","first-page":"451","article-title":"PEG-interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med","volume":"351","author":"RT Chung","year":"2004"},{"key":"ref12","first-page":"2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA","volume":"292","author":"F Carrat","year":"2004"},{"key":"ref13","first-page":"289","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology","volume":"24","author":"P Bedossa","year":"1996"},{"key":"ref14","first-page":"15","article-title":"Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS","volume":"22(1)","author":"L Martin-Carbonero","year":"2008"},{"key":"ref15","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. (2011) Departamento de DST, AIDS e Hepatites virais. Protocolo cl\u00ednico e diretrizes terap\u00eauticas para hepatite viral C e coinfec\u00e7\u00f5es. S\u00e9rie A. Normas e Manuais T\u00e9cnicos. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade. Available: http:\/\/portal.saude.gov.br\/portal\/arquivos\/pdf\/prot_clinico_diretrizes_tera_hepatite_c.pdf<\/ext-link>. Accessed 12 november 2012."},{"key":"ref16","first-page":"261","article-title":"Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV\/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr","volume":"58(3)","author":"AH Talal","year":"2011"},{"key":"ref17","first-page":"972","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses","volume":"23(8)","author":"M N\u00fa\u00f1ez","year":"2007"},{"key":"ref18","first-page":"88","article-title":"Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. J Viral Hepat","volume":"19(2)","author":"SM Alavian","year":"2012"},{"key":"ref19","first-page":"1302","article-title":"Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study","volume":"126(5)","author":"NH Afdhal","year":"2004","journal-title":"Gastroenterology"},{"key":"ref20","first-page":"185","article-title":"Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int","volume":"11(2)","author":"JW Yu","year":"2012"},{"key":"ref21","first-page":"2491","article-title":"Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol","volume":"98","author":"DT Dieterich","year":"2003"},{"key":"ref22","first-page":"504","article-title":"Epoetin alfa once weekly improves anemia in HIV\/hepatitis C virus-coinfected patients treated with interferon\/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr","volume":"39","author":"MS Sulkowski","year":"2005"},{"key":"ref23","first-page":"32","article-title":"Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C. Georgian Med News","volume":"175","author":"L Sharvadze","year":"2009"},{"key":"ref24","first-page":"150","article-title":"Sustained virological response according to the type of early virological response in HCV and HCV\/HIV. Ann Hepatol","volume":"9(2)","author":"PR Lerias de Almeida","year":"2010"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Chung HJ, Lee JW, Kim YS, Lee JI. (2013) Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area. Intervirology.[In press].","DOI":"10.1159\/000345539"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Bura M, Kowala-Piaskowska A, Adamek A, Bura A, Czajka A, et al<\/etal>.. (2012) Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre. Postepy Hig Med Dosw [serial online]. 66: 339\u201347. Available: www.phmd.pl<\/ext-link>. Accessed 12 December 2012.","DOI":"10.5604\/17322693.1000332"},{"key":"ref27","first-page":"198","article-title":"Treatment of chronic hepatitis C virus infection. A study of best predictors for response. Rev Esp Quimioter","volume":"24(4)","author":"NO Vanegas","year":"2011"},{"key":"ref28","first-page":"975","article-title":"Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus\/HIV coinfected patients. AIDS","volume":"24(7)","author":"E Van den Eynde","year":"2010"},{"key":"ref29","first-page":"70","article-title":"Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials","volume":"13(2)","year":"2012"},{"key":"ref30","first-page":"1301","article-title":"Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology","volume":"58(109)","author":"S Coban","year":"2011"},{"key":"ref31","first-page":"e81","article-title":"Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat","volume":"18(4)","author":"S Mauss","year":"2011"},{"key":"ref32","first-page":"1195","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med","volume":"364","author":"F Poordad","year":"2011"},{"key":"ref33","first-page":"45","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med","volume":"368(1)","author":"F Poordad","year":"2013"},{"key":"ref34","first-page":"2405","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med","volume":"364","author":"IM Jacobson","year":"2011"},{"key":"ref35","first-page":"34","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med","volume":"368(1)","author":"EJ Gane","year":"2013"},{"key":"ref36","first-page":"1433","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology","volume":"54(4)","author":"MG Ghany","year":"2011"},{"key":"ref37","first-page":"669","article-title":"Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol","volume":"107(5)","author":"HS Yee","year":"2012"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.2012.04992.x","article-title":"UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients","volume":"35(6)","author":"P Ramachandran","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkq086","article-title":"New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals","volume":"65(6)","author":"K Seden","year":"2010","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"ref40","unstructured":"Sulkowski M, S Pol, C Cooper, Fainboim J, Slim A, et al. Boceprevir+Pegylated Interferon+Ribavirin for the Treatment of HCV\/HIV-co-infected Patients: End of Treatment (Week-48) Interim Results. [Abstract 47]. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5\u20138, 2011; Seattle, WA."},{"key":"ref41","unstructured":"Dieterich DT, Soriano V, Sherman KE, Girard PM, Rockstroh JK, et al. Telaprevir in combination with peginterferon alfa-2a\/ribavirin in HCV\/HIV co-infected patients: SVR12 interim analysis.[Abstract 46]. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5\u20138, 2011; Seattle, WA."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0067734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T06:09:03Z","timestamp":1540015743000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0067734"}},"subtitle":[],"editor":[{"given":"Maureen J.","family":"Donlin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0067734","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,9]]}}}